

Dr. rer. nat. (USA) Arwed Burrichter



Patentanwalt

Partner seit 2002

Bleichstraße 14
D-40211 Düsseldorf

Telefon +49 211 90490-0
Telefax +49 211 90490-49

mail@cohausz-florack.de

Ausführliches Profil

Dr. Arwed Burrichter berät als Patentanwalt und Partner bei COHAUSZ & FLORACK führende, international tätige Unternehmen aus dem Chemie- und Life Sciences Sektor. Der promovierte Chemiker betreut Patente und Lizenzen vor allem aus den Bereichen Chemie & Life Sciences, pharmazeutische Chemie, Polymerchemie und Biochemie und berät Mandanten beim Aufbau ihrer Schutzrechtsportfolios. Arwed Burrichter hat umfangreiche Expertise und jahrelange Erfahrung mit Patentverletzungs-, Nichtigkeits- und Einspruchsverfahren, mit dem Schutz von Geschmacksmustern und mit dem Management von Markenbeständen. Zudem ist er als Autor und Referent im Chemie- und Pharmapatentrecht aktiv.

Nach seinem Chemiestudium in Bonn und Los Angeles promovierte Arwed Burrichter 1997 bei Nobelpreisträger George A. Olah an der University of Southern California in Los Angeles auf dem Gebiet der Kohlenwasserstoffchemie. Nach seiner Ausbildung zum Patentanwalt arbeitete er sechs Monate in der IP Litigation Practice Group von Fish & Neave LLP in New York und sammelte dort praktische Erfahrung im US-Patentrecht. Seit 2000 ist er als deutscher Patentanwalt und seit 2002 als Vertreter vor dem Europäischen Patentamt zugelassen.

Arwed Burrichter spricht Deutsch, Englisch und Französisch.

Empfehlungen

- Best Lawyers 2024
- [IAM Patent 1000 2023](#)

“Arwed Burrichter has a deep knowledge of his clients’ businesses. His advice is grounded in a trusting relationship and a good understanding of their business objectives and expectations. He is a good communicator, a smart arguer and efficient in patent prosecution and oppositions. He has a remarkable aptitude for managing large and complex files.”

- [Patent Star 2023 \(IP Stars\)](#)

- [Leaders League 2023](#)
(...) highly recommended for patent prosecution (...)
- [Legal 500 EMEA 2023](#)
"Outstanding patent attorney, judicial strategies and excellent detailed knowledge, is excellent at understanding the client and his needs."
- [Chambers Europe 2023](#)
- [Chambers Global 2023](#)
- [Legal 500 Deutschland 2023](#)
"Herausragender Patentanwalt, gerichtliche Strategien und exzellente Detailkenntnis, kann sich hervorragend in den Mandanten und seine Bedürfnisse eindenken."
- [IAM Global Leaders 2023](#)
- [Wiwo TOP-Anwalt 2022](#)
- [JUVE Patent 2022](#)
"extensive insider knowledge on dealing with the German Patent Office and Federal Patent Court", "a real authority and seasoned litigator", (competitors)
- [IAM Patent 1000 2022](#)
"Organic chemistry PhD Arwed Burrichter has all the skills needed to handle complex patent issues within the pharmaceutical field. Drawing on a deep playbook of attack and defence strategies, he has notched up numerous wins in high-profile EPO oppositions recently."
- [Best Lawyers 2023](#)
- [Legal 500 EMEA 2022](#)
- [Chambers Europe 2022](#)
- [Chambers Global 2022](#)
"He is a very capable team leader and he competently takes on this role."
- [Legal 500 Deutschland 2022](#)
- [IAM Global Leaders 2022](#)
- [JUVE Handbuch 2021/2022](#)
"highly experienced and knowledgeable. You always feel like you're in the very best hands" (competitor)
- [IAM Patent 1000 2021](#)
"Dr Burrichter's capacity for advocating and devising effective winning strategies makes him one of the most sought-after chemistry patent counsel in Germany. He has been consistently recognised in JUVE's patent category as one of Germany's most frequently recommended patent attorneys for chemistry-related matters."
- [Leaders League 2021](#)
Excellent in patent prosecution
- [Best Lawyers 2022](#)
- [The LEGAL 500 EMEA 2021](#)
- [Chambers Europe 2021](#)
"One client states: 'He has excellent technical skills and is very easy to work with.'"
- [Chambers Global 2021](#)
"Besides his litigation and EPO opposition work, Arwed maintains an extensive patent prosecution docket for his clients. His extensive international experience makes Arwed a sought after advisor for important strategic decisions in European patent prosecution and litigation matters."
- [The LEGAL 500 Deutschland 2021](#)
- [JUVE Handbuch 2020/2021](#)
Führender Berater unter Patentanwälten ("fachlich eine Instanz", Wettbewerber)
- [IAM Patent 1000 2020](#)
"Arwed Burrichter has cultivated a sterling reputation among leading international chemistry and life sciences entities as a complex problem-solver. He employs an interdisciplinary scheme of thinking tanks to years of experience in patent litigation, nullity and opposition proceedings and intangible asset management."
- [IAM Global Leaders 2020](#)
- [Best Lawyers 2020](#)
- [The LEGAL 500 EMEA 2020](#)
- [Chambers Global 2020](#)
- [The LEGAL 500 Deutschland 2020](#)
- [IAM Global Leaders 2020](#)
- [JUVE Handbuch 2019/2020](#)
Führender Name unter Patentanwälten
- [Wirtschaftswoche Ranking Patentanwälte 2019](#)
- [IAM Patent 1000, 2019](#)
(...) *"among the best for chemicals in Germany", "a strategic thinker with the ability to thoroughly immerse himself in the technical details" (...)*
- [Best Lawyers 2020](#)
- [Chambers Europe und Chambers Global 2019](#)
Leaders in their Field
- [JUVE Handbuch 2018/2019](#)
Führender Name unter Patentanwälten
- [Chambers Europe und Chambers Global 2018](#)
Leaders in their Field
- [The LEGAL 500 Deutschland 2018](#)

- Wirtschaftswoche Top Anwälte, 2018
- Expert Guides 2018
- IAM Patent 1000, 2018
"(...) On the non-contentious side of the practice, Arwed A Burrichter is a diligent portfolio builder who files with finesse and treats every patron as if they were his only one. (...)"
- Best Lawyers 2018
- Wirtschaftswoche 2018
- IAM Patent 1000, 2017
"(...) has notable expertise in supplementary protection certificate (SPC) issues. With five years of scientific and professional experience in the United States – including a stint at what at the time was one of New York's leading boutiques – he has a complete command of the country's legal system."
- JUVE Handbuch 2017/2018
Führender Name unter Patentanwälten
- The LEGAL 500 2017
- JUVE Handbuch 2016/2017
Führender Name unter Patentanwälten
- IAM Patent 1000, 2016
"(...) he has a flair for pan-European portfolio management. (...)"
- The LEGAL 500 2016
- JUVE Handbuch 2015/2016
Führender Name unter Patentanwälten
- IAM Patent 1000, 2015
"(...) does a sterling job for clients in the life sciences and pharmaceutical industries. (...)"

Werdegang

- seit 2000** Patentanwalt bei COHAUSZ & FLORACK
- 2000** Sechsmonatiges Secondment bei Fish & Neave LLP, New York
- 1997 - 2000** Ausbildung zum Patentanwalt bei COHAUSZ & FLORACK
- Promotion auf dem Gebiet der organischen Chemie bei Nobelpreisträger Prof. Dr. George Olah in Los Angeles (Ph.D.)
- Studium der Chemie an der University of Southern California, Los Angeles, USA (M.Sc.)
- Studium der Chemie an der Universität Bonn (Vordiplom)

Mitgliedschaften

Patentanwaltskammer, epi, GRUR, FICPI, AIPLA, GdCh, ACS

Technische Schwerpunkte

- Chemie
- Pharmazeutische Chemie
- Life Sciences
- Polymerchemie
- Technische Chemie
- Biochemie

Rechtliche Expertise

- Patente
- Marken

- Verletzungsverfahren
- Einsprüche und Nichtigkeitsverfahren
- Due Dilligence und FTO
- Rechtsbeständigkeitsgutachten und Recherchen zum Stand der Technik

Veröffentlichungen

Dr. Arwed Burrichter, Dr. Natalie Kirchhofer & Dr. Andreas Spinnrock

Germany becomes ready for the UPC and revises Patent Act

in: IAM Innovation & Invention Yearbook 2023, a supplement to IAM, published by Law Business Research

[zum Artikel](#)

Dr. Arwed Burrichter, Dr. Natalie Kirchhofer & Dr. Melanie Lödige

Tips and tricks on how to obtain patent protection for polymorphs

IAM Life Sciences: Key issues for senior life sciences executives 2022

[Download](#)

Dr. Arwed Burrichter, Dr. Natalie Kirchhofer, Dr. Lauren Schweizer

Germany revises Patent Act and clears way for UPC

IAM Innovation & Invention Yearbook 2022: Building IP value in the 21st century, a supplement to IAM, published by Law Business Research - IP Division

[Download](#)

Dr. Arwed Burrichter, Dr. Natalie Kirchhofer

COHAUSZ & FLORACK successful in defending Bayer's patent on the once-daily administration of rivaroxaban (Xarelto®)

Blog entry

[zum Artikel](#)

Dr. Arwed Burrichter, Dr. Natalie Kirchhofer

Second medical use patents and their potential for society and research

Blog entry

[zum Artikel](#)

Dr. Arwed Burrichter

Interview in IAM Global Leaders 2021

This article first appeared in IAM Global Leaders 2021: a supplement to IAM, published by Law Business Research

[Download](#)

Dr. Arwed Burrichter, Dr. Natalie Kirchhofer, Dr. Melanie Lödige

Second medical use claims in pharmaceutical patents – sharp sword or toothless tiger?

IAM Innovation & Invention Yearbook: Building IP value in the 21st century, a supplement to IAM, published by Law Business Research - IP Division

[Download](#)

Dr. Arwed Burrichter, Dr. Natalie Kirchhofer

Oral proceedings via video conference: The EPO Boards of Appeal propose to amend the Rules of Procedure

Blog entry

[zum Artikel](#)

Dr. Arwed Burrichter, Mathias Karlhuber, Dr. Natalie Kirchhofer

EPO decision on compulsory oral proceedings by videoconference

Blog entry

[zum Artikel](#)

Gottfried Schüll, Dr. Arwed Burrichter, Dr. Natalie Kirchhofer

New draft legislation in Germany to ratify the Unified Patent Court

Blog entry

[zum Artikel](#)

Dr. Arwed Burrichter, Dr. Natalie Kirchhofer, Andreas Spinnrock

Deadly pitfalls and lessons learned – claiming priority at the EPO

IAM Life Sciences: Key issues for senior life sciences executives 2020, a supplement to IAM, published by Globe Business Media Group - IP Division

[Download](#)

Dr. Arwed Burrichter, Dr. Natalie Kirchhofer

Handbuch Europäischer Patentprozess

Autoren der Kapitel: §14 Nichtigkeitsklage, §16 Nichtigkeitswiderklage und §18 Antrag auf Änderung des Patents

[zum Artikel](#)

Dr. Arwed Burrichter, Dr. Natalie Kirchhofer

EPO Administrative Council adopts new Rules of Procedure for the Boards of Appeal

Blog entry

[zum Artikel](#)

Dr. Arwed Burrichter, Dr. Natalie Kirchhofer, Dr. Simon Müller

Clinical trial disclosures – an obstacle to patentability in Europe

IAM Life Sciences: Key issues for senior life sciences executives 2019, a supplement to IAM, published by Globe Business Media Group - IP Division

[Download](#)

Dr. Arwed Burrichter, Dr. Natalie Kirchhofer, Dr. Romina Kühnle

Sprycel – new plausibility threshold for life sciences patents?

IAM Life Sciences: Key issues for senior life sciences executives 2018, a supplement to IAM, published by Globe Business Media Group - IP Division

[Download](#)

Dr. Arwed Burrichter, Dr. Natalie Kirchhofer, Dr. Romina Kühnle

The need-to-know facts about patent term extensions in Europe

Patents in Europe 2018/19: Helping business compete in the global economy, a supplement to IAM, published by Globe Business Media Group - IP Division

[Download](#)

Dr. Arwed Burrichter, Mathias Karlhuber, Dr. Natalie Kirchhofer

UPC could open as early as December 2017, if not blocked by a “hard” Brexit

Blog entry

[zum Artikel](#)

Dr. Arwed Burrichter

Der qualifizierte Hinweis nach §83 Abs. 1 PatG und seine Bedeutung für den Verletzungsprozess, Teil 1

Festschrift 80 Jahre Patentgerichtsbarkeit in Düsseldorf, Carl Heymanns Verlag 2016

Dr. Arwed Burrichter, Dr. Natalie Kirchhofer, Dr. Tobias Hoheisel

Using the UPC to your benefit in pharmaceuticals and life sciences

This article first appeared in IAM Life Sciences 2016, a supplement to Intellectual Asset Management

[Download](#)

Dr. Arwed Burrichter, Dr. Natalie Kirchhofer, Dr. Tobias Hoheisel

Proposed structure of the Unified Patent Court

Patents in Europe 2016/17, a supplement to Intellectual Asset Management, published by Globe Business Media Group - IP Division'

[Download](#)

Gottfried Schüll, Dr. Arwed Burrichter

Europe's litigation powerhouse (Interview)

Intellectual Asset Management issue 74, published by Globe Business Media Group - IP Division

[Download](#)

Dr. Ralph Minderop, Dr. Arwed Burrichter, Dr. Natalie Kirchhofer

Cross-border patent litigation in Europe: change is coming

IAM Life Sciences 2015, a supplement to Intellectual Asset Management

[Download](#)

Dr. Ralph Minderop, Dr. Arwed Burrichter, Dr. Romina Kühnle

Legal developments on the patentability of biotech inventions

The IP Media Group, Patents in Europe 2015/2016

[Download](#)

Dr. Ralph Minderop, Dr. Arwed Burrichter, Dr. Corinna Lueg

Federal court stakes new ground for reach-through claims

The IP Media Group, Patents in the life sciences industries 2014

[Download](#)

Dr. Ralph Minderop, Dr. Arwed Burrichter, Dr. Natalie Kirchhofer

Prodrugs and metabolites - in the twilight zone of patentability?

IAM Magazine, IP in the Life Sciences Industries 2013

[Download](#)

Dr. Ralph Minderop, Dr. Arwed Burrichter, Dr. Natalie Kirchhofer

The must-know facts about patent term extensions in Europe

IAM Magazine, Patents in Europe 2012/2013

[Download](#)

Dr. Ralph Minderop, Dr. Arwed Burrichter, Dr. Natalie Kirchhofer

EPO Enlarged Board of Appeal rules on disclaiming positive embodiments of an invention

IAM Magazine, September 2012

[Download](#)

Dr. Ralph Minderop, Dr. Arwed Burrichter, Dr. Natalie Kirchhofer

Key issues in building a strong life sciences patent portfolio

IAM Magazine, Juni 2012

[Download](#)

Dr. Ralph Minderop, Dr. Arwed Burrichter, Dr. Meikel Diepholz, Dr. Natalie Kirchhofer

Patenting biotechnology inventions via the EPO

Patents in Europe 2011/2012

[Download](#)

Dr. Ralph Minderop, Dr. Arwed Burrichter, Dr. Meikel Diepholz, Dr. Natalie Kirchhofer

Patent-Life Cycle-Management im Pharmabereich

transkript Nr. 11, 17. Jahrgang 2011

[Download](#)